News for Healthier Living

New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

Caris Life Sciences(r) (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients.

August 13, 2025


August 21 2025

August 20 2025

August 19 2025

August 18 2025

August 17 2025

August 16 2025

August 15 2025

August 14 2025

August 13 2025

August 12 2025

August 11 2025

August 10 2025

August 9 2025

August 8 2025

August 7 2025